Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure

European Journal of Heart Failure

Volumn 12, Issue 8, 2010, Pages 797-804

  Meili Butz, Silvia ^a   Bühler, Katrin ^a   John, Dietlinde ^a   Buser, Peter ^a   Vale, Wylie W ^b   Peterson, Kirk L ^c   Brink, Marijke ^a   Dieterle, Thomas ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Action potential duration; Corticotropin releasing factor related peptides; Left ventricular function; Urocortin 2; Ventricular fibrillation threshold

Indexed keywords

CALCIUM ION; UROCORTIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTRIC POTENTIAL; FLUOROMETRY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEMODYNAMIC PARAMETERS; HYPERTENSION; ISOLATED HEART; MALE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RAT;

ACUTE DISEASE; ANIMALS; ARRHYTHMIAS, CARDIAC; DISEASE MODELS, ANIMAL; FLUOROMETRY; HEART FAILURE; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; INTRACELLULAR CALCIUM-SENSING PROTEINS; MALE; MYOCARDIUM; PERFUSION; RATS; RATS, INBRED DAHL; SODIUM, DIETARY; UROCORTINS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION;

EID: 77955455052     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq054     Document Type: Article

References (36)

1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropinreleasing factor. Nature 1995;378:287-292.
2. Kishimoto T, Pearse RV 2nd, Lin CR, Rosenfeld MG. A sauvagine/ corticotropinreleasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 1995;92:1108-1112.
3. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001;98:2843-2848.
4. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci A 2001;98:7570-7575.
5. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropinreleasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000;279:H3031-H3039.
6. Ikeda K, Tojo K, Tokudome G, Ohta M, Sugimoto K, Tamura T, Tajima N, Mochizuki S, Kawakami M, Hosoya T. Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. Mol Cell Biochem 2003;252:25-32.
7. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004;106:383-388.
8. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004;101:3697-3702.
9. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 2002;40:1495-1505.
10. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005;112:3624-3632.
11. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 2006;27:2088-2098.
12. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM. Urocortin 2 infusion in human heart failure. Eur Heart J 2007;28:2589-2597.
13. Dieterle T, Belke DD, Bale TL, Vale WW, Hoshijima M, Chien KR, Pfisterer M, Buser P, Dillmann WH, Peterson KL. Effects of Urocortin II in isolated cardiac myocytes from the muscle LIM protein knock-out mouse, a model for dilated cardiomyopathy: bypass of blunted b-adrenergic response in heart failure. Circulation 2004;110:2810.
14. Tao J, Xu H, Yang C, Liu CN, Li S. Effect of urocortin on L-type calcium currents in adult rat ventricular myocytes. Pharmacol Res 2004;50:471-476.
15. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM, Latchman DS. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000;275:8508-8514.
16. Lawrence KM, Kabir AM, Bellahcene M, Davidson S, Cao XB, McCormick J, Mesquita RA, Carroll CJ, Chanalaris A, Townsend PA, Hubank M, Stephanou A, Knight RA, Marber MS, Latchman DS. Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB J 2005;19:831-833.
17. Kamp TJ, Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 2000;87:1095-1102.
18. Lakatta EG. Functional implications of spontaneous sarcoplasmic reticulum Ca2+ release in the heart. Cardiovasc Res 1992;26:193-214.
19. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;60:560-565. (Pubitemid 17138871)
20. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317: 787-792
21. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 2006;34:58-66.
22. Stevenson WG, Middlekauf HR, Saxon LR. Ventricular arrhythmias in heart failure. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology from Cell to Bedside. Philadelphia: W.B. Sauters Company; 1995. p848-863.
23. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation;58:1072-1083
24. Mahler F, Ross J Jr, O'Rourke RA, Covell JW. Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phase measures of contractility in the conscious dog. Am J Cardiol 1975;35:626-634.
25. Driamov S, Remondino A, Bellahcene M, Beier K, Ziegler A, Buser PT, Zaugg CE. Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia. J Pharm Pharmacol 2004;56:521-528.
26. Zaugg CE, Ziegler A, Lee RJ, Barbosa V, Buser PT. Postresuscitation stunning: postfibrillatory myocardial dysfunction caused by reduced myofilament Ca2+ responsiveness after ventricular fibrillation-induced myocyte Ca2+ overload. J Cardiovasc Electrophysiol 2002;13:1017-1024.
27. Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 2004;49:171-181.
28. Zaugg CE, Wu ST, Lee RJ, ParmleyWW, Buser PT, Wikman-Coffelt J. Importance of calcium for the vulnerability to ventricular fibrillation detected by premature ventricular stimulation: single pulse versus sequential pulse methods. J Mol Cell Cardiol 1996;28:1059-1072.
29. Van Tyn RA, MacLean LD. Ventricular fibrillation threshold. Am J Physiol 1961;201: 457-461.
30. Yoneda T, Kihara Y, Ohkusa T, Iwanaga Y, Inagaki K, Takeuchi Y, Hayashida W, Ueyama T, Hisamatsu Y, Fujita M, Hatac S, Matsuzaki M, Sasayama S. Calcium handling and sarcoplasmic-reticular protein functions during heart-failure transition in ventricular myocardium from rats with hypertension. Life Sci 2001;70:143-157.
31. Katz AM. Physiology of the Heart. 3rd ed. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams & illiams; 2001.
32. Liu CN, Yang C, Liu XY, Li S. In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol 2005;83:459-465.
33. Meili-Butz S, John D, Buser PT, Pfisterer M, Vale WW, Peterson KL, Brink M, Dieterle T. Acute antiarrhythmic effects of urocortin 2 in the isolated perfused rat heart. Kardiovask Med 2008;11(Suppl. 16):23S.
34. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998;39:89-105. (Pubitemid 28322382)
35. Cerbai E, Barbieri M, Li Q, Mugelli A. Ionic basis of action potential prolongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages. Cardiovasc Res 1994;28:1180-1187.
36. Viswanathan PC, Shaw RM, Rudy Y. Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation 1999;99: 2466-2474.